Innoviva, Inc. (INVA)
23.41
0.00 (0.00%)
USD |
NASDAQ |
Feb 24, 16:00
23.41
0.00 (0.00%)
After-Hours: 18:09
Innoviva Research and Development Expense (Quarterly) : 13.67M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Merck & Co., Inc. | 3.992B |
| Nektar Therapeutics | 27.25M |
| Regeneron Pharmaceuticals, Inc. | 1.481B |
| Oramed Pharmaceuticals, Inc. | 1.153M |
| Theravance Biopharma, Inc. | 7.707M |